EGFR and breast cancer: Delayed tumor onset in a transgenic mouse model of HER2+ breast cancer correlated with impaired Ras-mediated Erk activation, which argues that Ras-MAPK signaling from EGFR-HER2 potentiates tumor development and progression [12, 13].